GLP-3 RT30 is a synthetic multi-agonist research peptide utilized in laboratory and preclinical settings to investigate incretin receptor pathway signaling, metabolic regulation, and coordinated endocrine responses across multiple receptor systems. This higher-capacity 30mg formulation is commonly selected for studies involving GLP-associated receptor activity, glucose-dependent signaling pathways, and systemic energy homeostasis models.
 
Research applications frequently focus on GLP-3 RT30’s interaction with incretin-related receptors and downstream pathways, including cAMP activation, insulin secretagogue responses, glucagon modulation, and appetite-related neuroendocrine signaling. Additional investigations explore its role in lipid metabolism, glucose utilization efficiency, and adipose tissue signaling in controlled experimental environments.
 
Due to its multi-agonist profile, GLP-3 RT30 is often utilized in research evaluating integrated metabolic pathway interactions across multiple receptor systems, offering broader analytical insight compared to single- or dual-agonist compounds. The 30mg format is particularly suited for extended research protocols, repeated experimental runs, or higher-volume study designs.
 
This high-purity 30mg formulation is manufactured to strict laboratory standards and intended exclusively for analytical testing, in-vitro studies, and experimental research applications.
 
For research use only. Not for human consumption.
 
See product pictures for Certificates of Analysis.